Table 2.
Clinical response by PE-based chemotherapy.
| Response | Number of patients, (%) | ||
|---|---|---|---|
| Total (N=59) | PCE (n=19) | PTX+Cmab (n=40) | |
| Complete response (CR) | 3 (5.1) | 1 (5.3) | 2 (5.0) |
| Partial response (PR) | 34 (57.6) | 11 (57.9) | 23 (57.5) |
| Stable disease (SD) | 7 (11.9) | 3(15.8) | 4 (10.0) |
| Progressive disease | 13 (22.0) | 3 (15.8) | 10 (25.0) |
| Not evaluable | 2 (3.4) | 1 (5.3) | 1 (2.5) |
| ORR (%) | 37 (62.7) | 12 (63.2) | 25 (62.5) |
| DCR (%) | 44 (74.6) | 15 (78.9) | 29 (72.7) |
ORR, overall response rate; DCR, disease control rate; PTX+Cmab, paclitaxel+cetuximab; PCE, paclitaxel+carboplatin+cetuximab. ORR, proportion of CR+PR; DCR, proportion of CR+PR+SD.